Overview

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of the combination of bendamustine and ofatumumab in subjects with relapsed/refractory chronic lymphocytic leukemia and small cell lymphoma. All subjects enrolled on this study will receive both drugs by intravenous (IV) infusion.
Phase:
Phase 2
Details
Lead Sponsor:
Georgetown University
Collaborators:
Cephalon
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal
Bendamustine Hydrochloride
Ofatumumab